To date, several small-molecule compounds targeting PSMA have been developed for PET imaging in prostate cancer, showing an impact in many medical fields, such as radiology, radiation oncology, targeted radionuclide therapy, and intraoperative navigation. This evidence concerns the gene FOLH1 and prostate carcinoma.